Daprodustat in Dialysis (2021) — Trial Summary

Daprodustat in Dialysis (2021): ASCEND-D, a randomized, open-label phase 3 trial in 2,964 patients on dialysis with a hemoglobin of 8.0 to 11.5 g/dL, compared oral daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with an injectable ESA (epoetin alfa on hemodialysis, da

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.